Cure8 research brief
An experimental mouse study suggests gastrodin may reduce colitis severity and associated anxiety/depression-like behaviours while changing gut microbiota, metabolites, and intestinal inflammation — an early preclinical signal that could guide future research into gut–brain mechanisms relevant to IBD comorbidities.
Researchers of the gut–brain axis and microbiome, preclinical drug-discovery teams, clinicians interested in IBD comorbid mental health, and informed patients following early-stage research.
A mouse study reports that gastrodin (a component of the herb Gastrodia elata) reduced DSS-induced acute colitis and improved anxiety- and depression-like behaviours.
The authors measured colon length, histology, tight-junction protein Occludin, TNF-α, metagenomic changes in gut bacteria, metabolomics shifts (including taurine), and proteomic changes in the colon.
The results are correlative: gastrodin treatment was associated with changes in microbiota composition, metabolic pathways, intestinal barrier proteins, and local inflammation that accompanied improved colitis and behavioural readouts. The authors explicitly state that causal links through a gut–brain axis require direct experimental validation.
This work is preclinical (mouse model) and exploratory; it suggests gastrodin as a candidate for further mechanistic and translational studies rather than an evidence-backed therapy for people with IBD.
The study used a 3% DSS-induced acute colitis mouse model and reports correlative changes across microbiota, metabolomics, proteomics, and inflammatory markers. Authors note causal gut–brain mechanisms are not proven; this is preclinical research and not clinical evidence.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Ethics approval and consent to participate: Mice were kept in specific pathogen-free conditions and housed in cages with controlled temperature (20–25 °C) and light (12 h light/12 h dark) and with water and food available ad libitum. All experimental procedures were critiqued and approved by the Institutional Animal Care and Use Committee of Xuzhou Medical University in accordance with the guidelines described in the revised 2011 Chinese Regulations for the Administration of Affairs Concerning Experimental Animals. Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
IBD is increasingly linked with anxiety, depression, and cognitive symptoms; this study suggests gut microbes may change tryptophan metabolism in colitis and contribute to those brain-related symptoms, which could point...
IBD patients often have depression and anxiety that current anti-TNF biologics do not adequately treat. An engineered probiotic that both neutralizes local TNFα and promotes GABA-producing microbes could address...
The study suggests IBD patients can fall into two distinct gut-microbe/metabolite types that align with differences in disease severity and mental-health scores, which could help explain why patients with the same...
